# Patient-Trial Match Report

*Generated: 2026-01-05 18:34:44*

## Patient Profile

- **Age**: 54
- **Sex**: Female
- **Cancer Type**: ovarian cancer
- **Biomarkers**: BRCA1 germline mutation

**Clinical Description**:
> 54-year-old female with high-grade serous ovarian cancer, germline BRCA1 pathogenic variant. Initial diagnosis Stage IIIC, underwent optimal debulking followed by carboplatin/paclitaxel x6 + niraparib maintenance. First recurrence at 18 months (platinum-sensitive), re-challenged with carboplatin/gemcitabine with PR, continued niraparib. Second recurrence now at 14 months - again platinum-sensitive interval. CA-125 rising (85 -> 340). Considering platinum rechallenge vs clinical trial. No significant residual neuropathy. Interested in novel PARP combinations or antibody-drug conjugates. Excellent performance status.

- **Location Preference**: United States, Canada

## Search Summary

- **Search terms used**: 9
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 33
- **LLM scored**: 67

## ðŸŸ¢ HIGH Likelihood (27 trials)

### [NCT03564340](https://clinicaltrials.gov/study/NCT03564340)

**A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16Ã—CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers**

- **Sponsor**: Regeneron Pharmaceuticals
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Confirmed diagnosis of advanced, epithelial ovarian cancer
- Received multiple lines of platinum-containing therapy
- Documented relapse on or after the most recent line of therapy
- ECOG status of 0
- No brain metastases
- Patient has expressed interest in novel therapies

**? Uncertainties:**
- Specific organ and bone marrow function details are not provided

**Assessment:**
> The patient has advanced epithelial ovarian cancer, which matches the trial's inclusion criteria. She has received multiple lines of platinum therapy and has documented relapse, fitting the treatment line condition. The patient's ECOG status is acceptable, and there are no known brain metastases or disqualifying factors. Minor uncertainty exists regarding the details of organ function.

---

### [NCT05065021](https://clinicaltrials.gov/study/NCT05065021)

**Re-VOLVE: A Phase II Clinical Trial in Women With Ovarian Cancer Progressing Post-PARP Inhibitor With Treatment Adapted to Real-time Assessment of Evolving Genomic Resistance**

- **Sponsor**: University Health Network, Toronto
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 54
- Sex: female
- Cancer type: ovarian cancer
- Biomarkers: BRCA1 germline mutation
- ECOG status: 0
- Prior therapies: carboplatin, paclitaxel, niraparib, gemcitabine
- Brain metastases: none
- Relapsed disease is platinum-sensitive
- No limit to number of lines of prior systemic therapy

**? Uncertainties:**
- Adequate bone marrow, renal and hepatic function - details not provided
- Left ventricular ejection fraction (LVEF) > 50% - details not provided
- Measurable disease as per RECIST 1.1 - details not provided
- Archival tissue availability - details not provided

**Assessment:**
> The patient's cancer type and histology match the trial criteria, and she is a previously treated patient which aligns with the inclusion requirements. There are minor uncertainties regarding organ function and measurable disease, but the central criteria are fulfilled.

---

### [NCT05920798](https://clinicaltrials.gov/study/NCT05920798)

**MC220601, Folate Receptor Alpha Dendritic Cells (FRÎ±DCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)**

- **Sponsor**: Mayo Clinic
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 54
- Sex: female
- Cancer type: ovarian cancer
- Biomarkers: BRCA1 germline mutation
- ECOG status: 0
- Prior therapies: carboplatin, paclitaxel, niraparib, gemcitabine (platinum-sensitive recurrence)
- No brain metastases
- CA-125 rising (85 -> 340), indicating measurable disease

**? Uncertainties:**
- Organ function lab values (e.g., hemoglobin, ANC, platelet count, bilirubin, AST, creatinine clearance) needed for full assessment

**Assessment:**
> The patient's cancer type is high-grade serous ovarian cancer, which matches the trial's indication. The patient's recurrence is platinum-sensitive and they have the required ECOG status. They have prior systemic therapy, which aligns with the trial's inclusion of previously treated patients, as any number of prior therapies is allowed. The only uncertainties involve organ function lab values that are not provided.

---

### [NCT06580314](https://clinicaltrials.gov/study/NCT06580314)

**A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy**

- **Sponsor**: NRG Oncology
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has high-grade serous ovarian cancer
- Patient has BRCA1 germline mutation
- ECOG performance status is 0
- Patient completed first line platinum-based therapy with at least 6 cycles
- Patient has no brain metastases

**? Uncertainties:**
- Absolute neutrophil count (ANC)
- Platelets
- Hemoglobin
- Creatinine clearance (CrCL)
- Total bilirubin
- AST and ALT levels
- Cardiac function assessment

**Assessment:**
> The patient's cancer type matches the trial criteria for ovarian cancer, and the patient meets most of the standard eligibility criteria. There are several organ function values missing, but overall, the trial eligibility is likely met.

---

### [NCT03419689](https://clinicaltrials.gov/study/NCT03419689)

**Biomarker Discovery Project in High Grade Serous Ovarian Cancer**

- **Sponsor**: University Health Network, Toronto
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histological diagnosis of high-grade serous ovarian cancer
- Age is 54 which is above 18 years
- ECOG status is 0
- Life expectancy greater than 6 months implied by prior therapy response
- No brain metastases
- Willing to undergo blood or fluid collection and tumour biopsy

**? Uncertainties:**
- Archival tissue availability information not provided
- Adequate informed consent capability not explicitly stated

**Assessment:**
> The patient's cancer type aligns with the trial's focus on high-grade serous ovarian cancer. The patient is within the specified age range and has a suitable ECOG performance status, and there are no indications of brain metastases. While there is uncertainty about the availability of archival tissue and the capability to provide informed consent, the patient mostly meets the essential eligibility criteria.

---

### [NCT01174121](https://clinicaltrials.gov/study/NCT01174121)

**A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has high-grade serous ovarian cancer, which is included in the trial conditions.
- Patient is ECOG 0, which meets the performance status criteria.
- Patient is age 54, which falls within the age eligibility (18-72 years).
- Patient has measurable disease as indicated by rising CA-125 levels.

**âœ— Potential Conflicts:**
- Patient has received multiple lines of prior therapy, but the trial excludes those who are not refractory to at least second-line treatments.

**Assessment:**
> The patient's ovarian cancer diagnosis matches the trial's target indication. Although they've had prior therapies, they are likely refractory after multiple lines, which aligns with the trial's eligibility for previously treated patients. The patient meets the ECOG status and age criteria, indicating good overall health.

---

### [NCT03428802](https://clinicaltrials.gov/study/NCT03428802)

**A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability**

- **Sponsor**: Rutgers, The State University of New Jersey
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Diagnosis of ovarian cancer
- Has a BRCA1 germline mutation
- ECOG status is 0
- No brain metastases
- Prior therapies include chemotherapy for ovarian cancer

**? Uncertainties:**
- Laboratory values for absolute neutrophil count, platelets, hemoglobin, serum creatinine, total bilirubin, AST, ALT, albumin, INR, aPTT are not provided

**Assessment:**
> The patient's diagnosis of high-grade serous ovarian cancer with a BRCA1 germline mutation aligns well with the trial conditions. The patient's ECOG status of 0 also meets the performance status requirement. Although treatment history suggests the patient is not treatment-naive, this trial is designed for previously treated patients, which is appropriate. Further verification is needed regarding specific lab values to ensure all eligibility criteria are met.

---

### [NCT04657068](https://clinicaltrials.gov/study/NCT04657068)

**A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors**

- **Sponsor**: Artios Pharma Ltd
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has high-grade serous ovarian cancer
- Patient has a germline BRCA1 mutation
- ECOG status is 0
- Patient is female with advanced ovarian cancer and has previously received PARP inhibitors

**Assessment:**
> The patient's cancer type matches the trial's focus on ovarian cancer and she possesses the required BRCA1 mutation. She has previous systemic therapies, aligning with dose expansion criteria for previously treated patients. The ECOG performance status is within the acceptable range.

---

### [NCT05579366](https://clinicaltrials.gov/study/NCT05579366)

**Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors**

- **Sponsor**: Genmab
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed high-grade serous ovarian cancer
- Patient has received prior therapies including carboplatin and paclitaxel
- Patient has ECOG status 0 and excellent performance status
- Patient has a germline BRCA1 mutation

**Assessment:**
> The patient's cancer type, high-grade serous ovarian cancer, is included in the trial's indication, and she has received prior therapies as required. Her excellent ECOG status supports eligibility.

---

### [NCT06188520](https://clinicaltrials.gov/study/NCT06188520)

**A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors**

- **Sponsor**: AstraZeneca
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Female participant
- ECOG status 0
- History of prior adequate therapies including platinum agents
- Diagnosis of high-grade serous ovarian cancer

**Assessment:**
> The patient has high-grade serous ovarian cancer, which matches the conditions studied by the trial. The treatment history indicates she is a previously treated patient, which aligns with the trialâ€™s inclusion criteria for advanced or metastatic solid tumors requiring prior therapy. The ECOG status is acceptable, and there are no indicated brain metastases that would disqualify her. Overall, the patient meets the critical inclusion criteria.

---

### [NCT06395519](https://clinicaltrials.gov/study/NCT06395519)

**A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies**

- **Sponsor**: 858 Therapeutics, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has ovarian cancer, which is among the conditions studied in the trial.
- Patient has a germline BRCA1 mutation, which is relevant for this trial.
- Patient's ECOG status is 0, indicating excellent performance status.

**Assessment:**
> The patient's ovarian cancer aligns with the trial's studied conditions, and her germline BRCA1 mutation is relevant for preferential enrollment. The patient is previously treated but fits the criteria as the trial includes advanced solid tumors that have progressed after systemic therapy. No conflicting information was found in her profile.

---

### [NCT06630325](https://clinicaltrials.gov/study/NCT06630325)

**Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART): Adaptive Clinical Treatment (ACT)**

- **Sponsor**: OHSU Knight Cancer Institute
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has high-grade serous ovarian cancer, which matches the trial's inclusion criteria for advanced ovarian carcinoma.
- ECOG status of 0 indicates excellent performance status.
- Patient has prior therapies and solid disease history, confirming they are previously treated, which aligns with trial's requirement for documented progression after prior therapy.

**? Uncertainties:**
- Specific organ function lab data (e.g., ANC, platelet count, hemoglobin, creatinine, bilirubin, AST/ALT, INR/aPTT) is not provided.
- Details on potential toxicity recovery from prior therapies.
- SMMART-ACT therapy regimen recommendation based on pre-screening biopsy results is not available.

**Assessment:**
> The patient's cancer type matches the trial's focus on advanced ovarian carcinoma, and the patient is previously treated with documented progression, satisfying the treatment line criteria. While there are some uncertainties regarding lab values and other specific eligibility details, the primary eligibility criteria are met, leading to a high likelihood of eligibility.

---

### [NCT06843447](https://clinicaltrials.gov/study/NCT06843447)

**A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy**

- **Sponsor**: Merck Sharp & Dohme LLC
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Pathologically documented diagnosis of high-grade serous ovarian cancer
- ECOG status of 0
- Platinum-sensitive disease with radiographic evidence of disease progression occurring â‰¥6 months after the last dose of platinum-based therapy

**Assessment:**
> The patient's cancer type matches the trial's focus on high-grade serous ovarian cancer. The patient has received prior therapies but falls within the criteria for relapsed disease, having platinum-sensitive disease with significant interval after platinum therapy and meets the ECOG status requirement.

---

### [NCT02012699](https://clinicaltrials.gov/study/NCT02012699)

**Integrated Cancer Repository for Cancer Research**

- **Sponsor**: University of Nebraska
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Diagnosis of ovarian cancer
- Age is 54 (above 19 years)
- ECOG status is 0
- No brain metastases
- Able to provide informed consent
- Speaks English

**Assessment:**
> The patient's cancer type matches the trial's conditions, and the patient meets the age, ECOG status, and language criteria, suggesting high eligibility.

---

### [NCT02732860](https://clinicaltrials.gov/study/NCT02732860)

**Prospective Evaluation of Freshly Implanted Cancers in Mice to Test Drug Response in Matching Host**

- **Sponsor**: University Health Network, Toronto
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has advanced High Grade Serous Ovarian Cancer (recurrent disease with a life expectancy of at least 12 months)
- ECOG performance status 0

**Assessment:**
> The patient's cancer type is High Grade Serous Ovarian Cancer which is included in the trial conditions. The patient is also previously treated, which aligns with the eligibility for recurrent disease. The ECOG status of 0 meets the performance status requirement, thereby confirming high eligibility.

---

### [NCT03702309](https://clinicaltrials.gov/study/NCT03702309)

**Liquid Biopsy Evaluation and Repository Development at Princess Margaret**

- **Sponsor**: University Health Network, Toronto
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has ovarian cancer, which is a condition studied in the trial.
- Patient is 54 years old, which is above the minimum of 18 years.
- Patient has signed and dated an informed consent form for participation in clinical trials.
- Patient has an ECOG status of 0.
- Patient has no brain metastases.

**Assessment:**
> The patient's cancer type matches the indication studied in the trial and they meet the age and ECOG status requirements. There are no conflicts or uncertainties regarding the eligibility criteria.

---

### [NCT05039801](https://clinicaltrials.gov/study/NCT05039801)

**A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has high-grade serous ovarian cancer, which is confirmed as eligible for the trial.
- Patient is a 54-year-old female, meeting the age criteria.
- ECOG status is 0, which meets the performance status requirement.

**? Uncertainties:**
- Detailed organ function lab values are not provided, so organ function cannot be fully assessed.

**Assessment:**
> The patient's cancer type, treatment history, and ECOG performance status align well with the trial requirements. There is a high likelihood of eligibility, although organ function details are missing, which introduces a minor uncertainty.

---

### [NCT05005403](https://clinicaltrials.gov/study/NCT05005403)

**A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab**

- **Sponsor**: AbbVie
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 54
- Sex: female
- Cancer type: ovarian cancer
- Biomarkers: BRCA1 germline mutation
- ECOG status: 0
- Prior therapies: carboplatin, paclitaxel, niraparib, gemcitabine
- Brain metastases: none
- Patient interested in novel PARP combinations or antibody-drug conjugates
- patient has high-grade serous ovarian cancer which matches the trial conditions

**Assessment:**
> The patient's cancer type of high-grade serous ovarian cancer matches the trial's focus on this condition. The patient has an ECOG status of 0 and is interested in novel treatments, consistent with the trial's objective. Given the patient's extensive prior therapy history, they are likely eligible as the trial does not explicitly demand treatment-naive patients.

---

### [NCT05227326](https://clinicaltrials.gov/study/NCT05227326)

**First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors**

- **Sponsor**: City of Hope Medical Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type: ovarian cancer matches the trial conditions studied.
- Age: 54 (â‰¥ 18 years).
- ECOG performance status: 0 (â‰¤ 2).
- Life expectancy of > 3 months.
- No brain metastases reported.
- Prior therapies include those indicated for platinum-sensitive recurrent ovarian cancer.

**? Uncertainties:**
- Laboratory criteria such as ANC, platelets, bilirubin, AST, ALT, and creatinine clearance are unknown.
- Patient's willingness to provide archival tissue is unconfirmed.

**Assessment:**
> The patient's cancer type is ovarian cancer, which aligns with the trial's focus. She has already undergone prior therapies, which is acceptable for this trial as it is for patients with refractory solid tumors. Despite some uncertainties regarding laboratory criteria and willingness to provide archival tissue, the primary requirements are met.

---

### [NCT05787587](https://clinicaltrials.gov/study/NCT05787587)

**A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors**

- **Sponsor**: IDEAYA Biosciences
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has high-grade serous ovarian cancer.
- Patient has documented BRCA1 germline mutation.
- Patient is 54 years old, meeting the adult age requirement.
- Patient is ECOG 0, indicating excellent performance status.
- Patient has progressed on prior therapies, satisfying treatment line requirements.

**Assessment:**
> The patient's cancer type matches the trial's focus on ovarian cancer, the patient has the required BRCA1 mutation, and she is previously treated, all of which align with the study's eligibility criteria.

---

### [NCT05694715](https://clinicaltrials.gov/study/NCT05694715)

**Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes**

- **Sponsor**: University of California, San Francisco
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has high-grade serous ovarian cancer, which is included in the trial conditions studied.
- Patient has a BRCA1 germline mutation, which is included in the trial conditions studied.
- Patient is 54 years old, which is above the minimum required age of 18.
- ECOG Performance Status is 0, which meets the requirement of <=1.
- Patient has no brain metastases.

**? Uncertainties:**
- Organ function labs (ANC, Hgb, platelets, AST, ALT, total bilirubin, creatinine) are not provided.
- Confirmation of no grade 2 or higher toxicity from prior treatments (except for neuropathy) is not explicitly stated.

**Assessment:**
> The patient's cancer type is directly aligned with the trial focus, and she meets the necessary age and ECOG performance status criteria. The main uncertainties lie in organ function assessments and toxicity recovery which, if confirmed, could further solidify her eligibility. Overall, she appears to fit well with the trial's requirements.

---

### [NCT05799274](https://clinicaltrials.gov/study/NCT05799274)

**Characterizing the Radiochemical and Radiation Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Ductal Adenocarcinoma or Other Solid Tumors**

- **Sponsor**: Radiopharm Theranostics, Ltd
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has high-grade serous ovarian cancer, which is included in the trial conditions studied.
- Patient is 54 years old, which meets the age requirement (â‰¥ 18 years).
- Patient has ECOG status of 0, which is acceptable.
- Patient has a life expectancy of â‰¥ 12 weeks.
- Patient has no brain metastases.

**? Uncertainties:**
- Screening laboratory values are not provided (WBC, ANC, Platelets, Hemoglobin, Creatinine, AST/ALT, Bilirubin).
- Baseline pulse oximetry value is not provided.
- ECG results are not provided.
- Confirmation of no history of anaphylactic reaction or other specific medical conditions that could affect eligibility.

**Assessment:**
> The patient's cancer type matches the trial's inclusion criteria for ovarian cancer, and their treatment history suggests they are not treatment-naive but have undergone several lines of therapy. There are some uncertainties around screening values and other criteria that are not explicitly provided, but overall criteria are likely met.

---

### [NCT06177171](https://clinicaltrials.gov/study/NCT06177171)

**A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors**

- **Sponsor**: Pamela Munster
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has advanced solid tumors with a germline BRCA1 mutation.
- Patient has ECOG status of 0.
- Patient demonstrates interest in novel PARP combinations which aligns with the trial's focus.

**? Uncertainties:**
- Specific lab values for organ function (e.g., hemoglobin, neutrophil count, liver function tests, creatinine) are not provided.

**Assessment:**
> The patient's diagnosis of high-grade serous ovarian cancer with a germline BRCA1 mutation aligns with the trial's inclusion criteria, and her ECOG status meets the requirements. However, organ function lab values are not explicitly provided, which introduces some uncertainty.

---

### [NCT06910657](https://clinicaltrials.gov/study/NCT06910657)

**A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors**

- **Sponsor**: ViroMissile, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has advanced ovarian cancer, which is included in the trial conditions studied.
- Patient is 54 years old, meeting the age criterion of â‰¥ 18 years.
- Patient's ECOG status is 0, which is acceptable as it is â‰¤ 1.

**? Uncertainties:**
- Adequate organ and bone marrow function is not specified in patient data.
- Specific details about measurable disease per RECIST v1.1 are not provided.

**Assessment:**
> The patient's cancer type matches the trial's indication, and the patient meets the age and ECOG performance status criteria. The treatment line appears appropriate as the trial does not specifically require treatment-naive patients. However, details regarding organ function and measurable disease are not confirmed, leading to a high confidence score without exclusions.

---

### [NCT04314401](https://clinicaltrials.gov/study/NCT04314401)

**Cancer Moonshot Biobank Research Protocol**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 80%

**âœ“ Supporting Factors:**
- Patient has high grade serous ovarian cancer which matches the conditions studied.
- ECOG status is 0, which is acceptable.
- Patient is 54 years old, meeting the age requirement.

**? Uncertainties:**
- Patient's ability to provide fresh biospecimens at enrollment is not specified.
- Confirmation on archival tissue availability not provided.
- No details on blood collection timing or feasibility.

**Assessment:**
> The patient's condition of high grade serous ovarian cancer aligns with the trial's focus on ovarian carcinoma. The patient has previously received treatment, aligning with the trial's inclusion of treatment-experienced patients. Age and ECOG status meet the trial's eligibility criteria, ensuring a solid match despite some uncertainties regarding biospecimen collection.

---

### [NCT05512208](https://clinicaltrials.gov/study/NCT05512208)

**A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)**

- **Sponsor**: University of Oklahoma
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Patient has high-grade serous ovarian cancer, which is one of the conditions studied in the trial.
- Patient is female and over 18 years old.
- Patient has a performance status of 0 (ECOG status â‰¤ 2).
- Patient has measurable disease with a rising CA-125 (indicative of recurrent disease).
- Patient has received prior systemic therapies for metastatic disease, satisfying the requirement for at least one prior systemic therapy.

**? Uncertainties:**
- Biomarker status for RAS or BRAF mutations is not provided; it is required for eligibility.
- Laboratory parameters for adequate organ function are not provided.

**Assessment:**
> The patient's cancer type matches the trial criteria as she has high-grade serous ovarian cancer. She has a history of prior systemic therapies, which is consistent with eligibility for this study targeting previously treated patients. However, key information regarding biomarker mutations and specific laboratory parameters are missing, which creates some uncertainty about eligibility.

---

### [NCT06971744](https://clinicaltrials.gov/study/NCT06971744)

**Autophagy Maintenance (AUTOMAIN) Therapy in High-Grade Serous Ovarian Cancer: A Phase II Trial**

- **Sponsor**: Medical University of South Carolina
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 70%

**âœ“ Supporting Factors:**
- Patient has platinum-sensitive first recurrent high-grade serous ovarian cancer.
- Patient has undergone genetic testing with known germline BRCA1 mutation.
- Patient has excellent ECOG performance status (0).
- Patient does not have brain metastases.

**âœ— Potential Conflicts:**
- Patient has not received at least 3-courses of bevacizumab during chemotherapy.

**? Uncertainties:**
- Bilirubin and liver function tests (AST/ALT) results are not provided.
- Creatinine clearance (CrCl) results are not provided.
- Absolute neutrophil count (ANC) is not provided.
- Platelet count is not provided.
- Hemoglobin level is not provided.

**Assessment:**
> The patient's cancer type matches the trial's focus on high-grade serous ovarian cancer, and she meets the requirement of being platinum-sensitive and having a known BRCA1 mutation. However, she has not received enough courses of bevacizumab as required, which may impact eligibility. Other lab values necessary for complete assessment are not provided, contributing to the medium confidence level.

---

## ðŸŸ  LOW Likelihood (1 trials)

### [NCT06365853](https://clinicaltrials.gov/study/NCT06365853)

**A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression**

- **Sponsor**: AbbVie
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Patient has a confirmed diagnosis of ovarian cancer.
- Patient has a BRCA1 mutation and has received prior treatment with PARP inhibitors.

**âœ— Potential Conflicts:**
- The trial requires participants to have high folate receptor alpha (FRÎ±) expression, which is not confirmed in the patient's profile.
- Patient has previously received carboplatin and other therapies, which may conflict with trial's treatment requirements.

**? Uncertainties:**
- Patient's folate receptor alpha (FRÎ±) expression status is unknown.
- Ocular health or history is not provided, which may affect eligibility.

**Assessment:**
> The patient has ovarian cancer and a BRCA1 mutation but lacks confirmation on the required FRÎ± expression for trial eligibility. Additionally, their treatment history raises questions about the treatment line requirements.

---

## Excluded (72 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT04251052](https://clinicaltrials.gov/study/NCT04251052) | Patient age 54 is above maximum age 50 |
| [NCT02693535](https://clinicaltrials.gov/study/NCT02693535) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04065269](https://clinicaltrials.gov/study/NCT04065269) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05128825](https://clinicaltrials.gov/study/NCT05128825) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05327010](https://clinicaltrials.gov/study/NCT05327010) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05554328](https://clinicaltrials.gov/study/NCT05554328) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05684965](https://clinicaltrials.gov/study/NCT05684965) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05819853](https://clinicaltrials.gov/study/NCT05819853) | Patient age 54 is above maximum age 35 |
| [NCT05902988](https://clinicaltrials.gov/study/NCT05902988) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05985655](https://clinicaltrials.gov/study/NCT05985655) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06660654](https://clinicaltrials.gov/study/NCT06660654) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06732336](https://clinicaltrials.gov/study/NCT06732336) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT00823654](https://clinicaltrials.gov/study/NCT00823654) | Patient age 54 is above maximum age 44 |
| [NCT01102569](https://clinicaltrials.gov/study/NCT01102569) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT02296307](https://clinicaltrials.gov/study/NCT02296307) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03568630](https://clinicaltrials.gov/study/NCT03568630) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03905941](https://clinicaltrials.gov/study/NCT03905941) | Patient age 54 is above maximum age 49 |
| [NCT04196595](https://clinicaltrials.gov/study/NCT04196595) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04294927](https://clinicaltrials.gov/study/NCT04294927) | Patient age 54 is above maximum age 50 |
| [NCT04389632](https://clinicaltrials.gov/study/NCT04389632) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 13 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT05300711](https://clinicaltrials.gov/study/NCT05300711) | University of Britis | Patient has a BRCA1 germline mutation which is an exclusion criterion for the trial. |
| [NCT06297525](https://clinicaltrials.gov/study/NCT06297525) | Step Pharma, SAS | The trial requires advanced disease not curable by available therapies; patient has prior systemic therapy which may lead to questionability on current disease status. |
| [NCT04918186](https://clinicaltrials.gov/study/NCT04918186) | Canadian Cancer Tria | Patient has platinum-sensitive ovarian cancer, while trial requires platinum-resistant high-grade serous ovarian cancer. |
| [NCT05281471](https://clinicaltrials.gov/study/NCT05281471) | Genelux Corporation | Patient has had prior treatments which indicates she is not treatment-naive, while trial is focused on platinum-resistant/refractory ovarian cancer. |
| [NCT05610735](https://clinicaltrials.gov/study/NCT05610735) | Sham Sunder Kakar | Patient is platinum-sensitive with multiple recurrences; trial requires patients that have become platinum resistant or have refractory disease. |
| [NCT05998135](https://clinicaltrials.gov/study/NCT05998135) | Emory University | Patient has platinum-sensitive ovarian cancer but the trial is for platinum-resistant ovarian cancer. |
| [NCT05961124](https://clinicaltrials.gov/study/NCT05961124) | Sunnybrook Health Sc | Patient has received multiple previous lines of treatment (carboplatin, paclitaxel, niraparib, gemcitabine), whereas trial includes only treatment-naive patients |
| [NCT06290193](https://clinicaltrials.gov/study/NCT06290193) | Memorial Sloan Kette | Patient has had prior systemic therapy (carboplatin, paclitaxel, niraparib, gemcitabine) whereas the trial does not specify eligibility for previously treated patients. |
| [NCT06639074](https://clinicaltrials.gov/study/NCT06639074) | Mayo Clinic | The trial's exclusion criteria states that no pathogenic mutations of BRCA1/BRCA2 are allowed. The patient has a BRCA1 germline mutation. |
| [NCT00005095](https://clinicaltrials.gov/study/NCT00005095) | Northwestern Univers | Trial studies HEREDITARY Breast/Ovarian CANCER, patient has OVARIAN CANCER without indication of increased risk for familial history. |
| [NCT03943316](https://clinicaltrials.gov/study/NCT03943316) | New Mexico Cancer Re | Patient has high-grade serous ovarian cancer, but trial requires pathological diagnosis or clinical suspicion and specifically states it is for women undergoing cytoreductive surgery, which the patient is not currently scheduled for. |
| [NCT04794322](https://clinicaltrials.gov/study/NCT04794322) | Massachusetts Genera | Patient has a history of advanced ovarian cancer (Stage IIIC) and multiple prior therapies, while the trial includes only patients who are treatment-naive or undergoing a risk-reducing surgery. |
| [NCT05636111](https://clinicaltrials.gov/study/NCT05636111) | M.D. Anderson Cancer | The trial targets platinum-resistant ovarian cancer, while the patient has platinum-sensitive ovarian cancer. |
| [NCT06799065](https://clinicaltrials.gov/study/NCT06799065) | Accent Therapeutics | Patient is not platinum-resistant, platinum-refractory, or platinum-intolerant as required by the trial for expansion cohorts |
| [NCT06677190](https://clinicaltrials.gov/study/NCT06677190) | Dana-Farber Cancer I | Patient has high-grade serous ovarian cancer, while trial targets clear cell carcinoma of the ovary. |
| [NCT02288676](https://clinicaltrials.gov/study/NCT02288676) | McGill University | Patient has previously treated ovarian cancer, while the trial conditions require subjects to have suspected or confirmed cancer of the upper genital tract and does not specify eligibility for previously treated patients. |
| [NCT04431024](https://clinicaltrials.gov/study/NCT04431024) | National Cancer Inst | Patient has ovarian cancer while trial focuses on BAP1 mutation and related syndromes which do not include ovarian cancer. |
| [NCT04847063](https://clinicaltrials.gov/study/NCT04847063) | National Cancer Inst | Patient has a history of prior systemic therapy, while the trial likely requires treatment-naive patients. |
| [NCT04890613](https://clinicaltrials.gov/study/NCT04890613) | Senhwa Biosciences,  | Trial requires BRCA2 and/or PALB2 mutation, the patient has a BRCA1 mutation only. |
| [NCT05287451](https://clinicaltrials.gov/study/NCT05287451) | M.D. Anderson Cancer | Patient is postmenopausal due to cancer treatment, while trial requires premenopausal status. |
| ... | ... | *and 19 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| BRCA1 germline mutation | manual | 1.0 |
| ovarian cancer | manual | 1.0 |
| BRCA1 germline mutation ovarian cancer | manual | 1.0 |
| BRCA1 germline mutation high-grade serous ovarian cancer | llm | 0.9 |
| BRCA1 mutation ovarian cancer | llm | 0.9 |
| high-grade serous ovarian cancer | llm | 0.8 |
| ovarian carcinoma | llm | 0.8 |
| BRCA1 pathogenic variant | llm | 0.9 |
| BRCA1 | llm | 0.9 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
- **Cardiac status/QTc interval** - relevant for trials with cardiotoxicity risk
